Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Analyst upgrades dominated the tape this week, with technology and healthcare taking the most attention.
MRVL led the semiconductor pack. The consensus target on Marvell Technology rose to $311.97 from $308.60, with 16 buys and no sell ratings. The chip designer is riding strong AI infrastructure tailwinds heading into its next earnings cycle.
MSFT also saw its consensus target nudge higher, up to $587.63 from $585.61. All 55 covering analysts hold a buy or hold rating, with only one sell on the book. The target drift reflects steady confidence rather than a sharp re-rating.
Pharma saw mixed moves. LLY edged higher to $1,329, with 25 buys out of 29 analysts. REGN saw its target lifted to $855.92, though 18 of 27 analysts carry a sell. bucked the trend with a small target trim, down to $390.84. Separately, ORTEX Medicare data shows Advantage penetration hit a record 51.1% in June, a macro read that benefits large managed-care and specialty pharma operators.
DAL took a quiet cut, with the average target slipping to $101.60 from $101.85. All 24 analysts remain buyers, but the trim suggests some near-term caution on airline margins.
STZ and DIS both saw minor target reductions, part of a small wave of defensive downgrades across consumer names.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
